Search

Your search keyword '"Martínez Sánchez, Pilar"' showing total 12 results
Start Over Author "Martínez Sánchez, Pilar" Publisher american society of hematology
12 results on '"Martínez Sánchez, Pilar"'

1. Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

Author

Martínez Sánchez, Pilar, primary, Zugmaier, Gerhard, additional, Gordon, Paul, additional, Jabbour, Elias, additional, Rifón Roca, José J., additional, Schwartz, Stefan, additional, Borlenghi, Erika, additional, Huguet, Francoise, additional, Hernández-Rivas, Jesús María, additional, Lussana, Federico, additional, Berthon, Céline, additional, Kadu, Priti, additional, Wong, Hansen, additional, Markovic, Ana, additional, Katlinskaya, Yuliya, additional, and Rambaldi, Alessandro, additional

Published
2022
Full Text
View/download PDF

2. Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Author

Sargas, Claudia, primary, Ayala, Rosa, additional, Larrayoz, Maria Jose, additional, Chillon, Carmen, additional, Carrillo, Estrella, additional, Bilbao, Cristina, additional, Prados de La Torre, Esther, additional, Martinez-Cuadron, David, additional, Rodríguez-Veiga, Rebeca, additional, Gil, Cristina, additional, Bernal, Teresa, additional, Bergua Burgués, Juan Miguel, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martínez Sánchez, Pilar, additional, Soria, Elena, additional, Serrano, Josefina, additional, Alonso Dominguez, Juan Manuel, additional, García-Boyero, Raimundo, additional, Amigo, Maria Luz, additional, Herrera, Pilar, additional, Sayas, María J., additional, Lavilla, Esperanza, additional, Martínez-López, Joaquín, additional, Calasanz, María José, additional, García-Sanz, Ramón, additional, Perez-Simon, Jose A., additional, Gómez-Casares, María Teresa, additional, Sánchez-Garcia, Joaquín, additional, Barragán, Eva, additional, and Montesinos, Pau, additional

Published
2022
Full Text
View/download PDF

3. Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Author

Suárez, Edwin Uriel, primary, Alonso, Juan Manuel, additional, Boluda, Blanca, additional, Lavilla, Esperanza, additional, Tormo, Mar, additional, Botella, Carmen, additional, Vives, Susana, additional, Rodriguez, Carlos, additional, Serrano, Josefina, additional, Sayas, María José, additional, Martínez Sánchez, Pilar, additional, Ramos, Fernando, additional, Bernal del Castillo, Teresa, additional, Algarra, Lorenzo, additional, Bergua Burgués, Juan Miguel, additional, Pérez-Simón, José, additional, Herrera, Pilar, additional, Barrios-García, Manuel, additional, Noriega-Concepción, Víctor, additional, Raposo-Puglia, Jóse Ángel, additional, Ayala, Rosa, additional, Barragán, Eva, additional, Martinez-Cuadron, David, additional, and Montesinos, Pau, additional

Published
2022
Full Text
View/download PDF

4. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

Author

Martínez-Cuadrón, David, primary, Megías-Vericat, Juan E., additional, Serrano, Josefina, additional, Martínez-Sánchez, Pilar, additional, Rodríguez-Arbolí, Eduardo, additional, Gil, Cristina, additional, Aguiar, Eliana, additional, Bergua, Juan, additional, López-Lorenzo, José L., additional, Bernal, Teresa, additional, Espadana, Ana, additional, Colorado, Mercedes, additional, Rodríguez-Medina, Carlos, additional, López-Pavía, María, additional, Tormo, Mar, additional, Algarra, Lorenzo, additional, Amigo, María-Luz, additional, Sayas, María J., additional, Labrador, Jorge, additional, Rodríguez-Gutiérrez, Juan I., additional, Benavente, Celina, additional, Costilla-Barriga, Lissette, additional, García-Boyero, Raimundo, additional, Lavilla-Rubira, Esperanza, additional, Vives, Susana, additional, Herrera, Pilar, additional, García-Belmonte, Daniel, additional, Herráez, María Mar, additional, Vasconcelos Esteves, Graça, additional, Gómez-Roncero, Maria I., additional, Cabello, Ana, additional, Bautista, Guiomar, additional, Balerdi, Amaia, additional, Mariz, José, additional, Boluda, Blanca, additional, Sanz, Miguel Á., additional, and Montesinos, Pau, additional

Published
2022
Full Text
View/download PDF

5. Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Author

Martínez Sánchez, Pilar, primary, Gordon, Paul, additional, Schwartz, Stefan, additional, Rossi, Giuseppe, additional, Huguet, Francoise, additional, Hernández-Rivas, Jesus Maria, additional, Kadu, Priti, additional, Wong, Hansen L., additional, Markovic, Ana, additional, Katlinskaya, Yuliya, additional, Panwar, Bharat, additional, and Zugmaier, Gerhard, additional

Published
2021
Full Text
View/download PDF

6. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Author

Ribera, Josep-Maria, Morgades, Mireia, Ciudad, Juana, Montesinos, Pau, Esteve, Jordi, Genescà, Eulàlia, Barba, Pere, Ribera, Jordi, García-Cadenas, Irene, Moreno, María José, Martínez-Carballeira, Daniel, Torrent, Anna, Martínez-Sánchez, Pilar, Monsalvo, Silvia, Gil, Cristina, Tormo, Mar, Artola, María Teresa, Cervera, Marta, González-Campos, José A., Rodríguez, Carlos, Bermudez, A., Novo, Andrés, Soria, Beatriz, Coll, Rosa, Amigo, María Luz, López-Martínez, Aurelio, Fernández, Rosa, Serrano, Josefina, Mercadal, Santiago, Cladera, Antonia, Giménez-Conca, Alberto, Peñarrubia, María J., Abella, Eugènia, Vall‐Llovera, Ferran, Hernández, Jesús M., Garcia-Guiñon, Antonio, Bergua, Juan, Rueda, Beatriz de, Sánchez-Sánchez, María-José, Serrano, Alfons, Calbacho, M., Alonso, Natalia, Méndez, Jose-Angel, García-Boyero, Raimundo, Olivares, Matxalen, Barrena, Susana, Zamora, Lurdes, Granada, Isabel, Lhermitte, Ludovic, Feliu, Evarist, Orfao, Alberto, Ribera, Josep-Maria, Morgades, Mireia, Ciudad, Juana, Montesinos, Pau, Esteve, Jordi, Genescà, Eulàlia, Barba, Pere, Ribera, Jordi, García-Cadenas, Irene, Moreno, María José, Martínez-Carballeira, Daniel, Torrent, Anna, Martínez-Sánchez, Pilar, Monsalvo, Silvia, Gil, Cristina, Tormo, Mar, Artola, María Teresa, Cervera, Marta, González-Campos, José A., Rodríguez, Carlos, Bermudez, A., Novo, Andrés, Soria, Beatriz, Coll, Rosa, Amigo, María Luz, López-Martínez, Aurelio, Fernández, Rosa, Serrano, Josefina, Mercadal, Santiago, Cladera, Antonia, Giménez-Conca, Alberto, Peñarrubia, María J., Abella, Eugènia, Vall‐Llovera, Ferran, Hernández, Jesús M., Garcia-Guiñon, Antonio, Bergua, Juan, Rueda, Beatriz de, Sánchez-Sánchez, María-José, Serrano, Alfons, Calbacho, M., Alonso, Natalia, Méndez, Jose-Angel, García-Boyero, Raimundo, Olivares, Matxalen, Barrena, Susana, Zamora, Lurdes, Granada, Isabel, Lhermitte, Ludovic, Feliu, Evarist, and Orfao, Alberto

Abstract

The need for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with Philadelphia chromosome–negative (Ph−) acute lymphoblastic leukemia (ALL) with high-risk (HR) features and adequate measurable residual disease (MRD) clearance remains unclear. The aim of the ALL-HR-11 trial was to evaluate the outcomes of HR Ph− adult ALL patients following chemotherapy or allo-HSCT administered based on end-induction and consolidation MRD levels. Patients aged 15 to 60 years with HR-ALL in complete response (CR) and MRD levels (centrally assessed by 8-color flow cytometry) <0.1% after induction and <0.01% after early consolidation were assigned to receive delayed consolidation and maintenance therapy up to 2 years in CR. The remaining patients were allocated to allo-HSCT. CR was attained in 315/348 patients (91%), with MRD <0.1% after induction in 220/289 patients (76%). By intention-to-treat, 218 patients were assigned to chemotherapy and 106 to allo-HSCT. The 5-year (±95% confidence interval) cumulative incidence of relapse (CIR), overall survival (OS), and event-free survival probabilities for the whole series were 43% ± 7%, 49% ± 7%, and 40% ± 6%, respectively, with CIR and OS rates of 45% ± 8% and 59% ± 9% for patients assigned to chemotherapy and of 40% ± 12% and 38% ± 11% for those assigned to allo-HSCT, respectively. Our results show that avoiding allo-HSCT does not hamper the outcomes of HR Ph− adult ALL patients up to 60 years with adequate MRD response after induction and consolidation. Better postremission alternative therapies are especially needed for patients with poor MRD clearance.

Published
2021

7. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Author

Ribera, Josep-Maria, primary, Morgades, Mireia, additional, Ciudad, Juana, additional, Montesinos, Pau, additional, Esteve, Jordi, additional, Genescà, Eulàlia, additional, Barba, Pere, additional, Ribera, Jordi, additional, García-Cadenas, Irene, additional, Moreno, María José, additional, Martínez-Carballeira, Daniel, additional, Torrent, Anna, additional, Martínez-Sánchez, Pilar, additional, Monsalvo, Silvia, additional, Gil, Cristina, additional, Tormo, Mar, additional, Artola, María Teresa, additional, Cervera, Marta, additional, González-Campos, José, additional, Rodríguez, Carlos, additional, Bermúdez, Arancha, additional, Novo, Andrés, additional, Soria, Beatriz, additional, Coll, Rosa, additional, Amigo, María-Luz, additional, López-Martínez, Aurelio, additional, Fernández-Martín, Rosa, additional, Serrano, Josefina, additional, Mercadal, Santiago, additional, Cladera, Antònia, additional, Giménez-Conca, Alberto, additional, Peñarrubia, María-Jesús, additional, Abella, Eugènia, additional, Vall-llovera, Ferran, additional, Hernández-Rivas, Jesús-María, additional, Garcia-Guiñon, Antoni, additional, Bergua, Juan-Miguel, additional, de Rueda, Beatriz, additional, Sánchez-Sánchez, María-José, additional, Serrano, Alfons, additional, Calbacho, María, additional, Alonso, Natalia, additional, Méndez-Sánchez, Jose-Ángel, additional, García-Boyero, Raimundo, additional, Olivares, Matxalen, additional, Barrena, Susana, additional, Zamora, Lurdes, additional, Granada, Isabel, additional, Lhermitte, Ludovic, additional, Feliu, Evarist, additional, and Orfao, Alberto, additional

Published
2021
Full Text
View/download PDF

8. Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Author

Bergua Burgues, Juan Miguel M., primary, Cano-Ferri, Isabel, additional, Martínez-Cuadron, David, additional, Boluda, Blanca, additional, Martínez-Sánchez, Pilar, additional, Rodríguez-Veiga, Rebeca, additional, Esteve, Jordi, additional, Vives, Susana, additional, Serrano, Josefina, additional, Vidriales, Maria-Belen, additional, Salamero, Olga, additional, Carretero, Carlos, additional, Jimenez-Ubieto, Ana, additional, Casas, Ignacio, additional, Cardesa, Rocio, additional, Diaz-Beyá, Marina, additional, Brunet, Salut, additional, Benavente, Celina, additional, Pérez-Simón, Jose Antonio, additional, Moscardo, Federico, additional, Aguiar, Eliana, additional, Perez Encinas, Manuel, additional, Martínez, Aurelio López, additional, Rguez, Carlos, additional, Cabello, A., additional, Labrador, Jorge, additional, Costilla, Lissette Del Pilar, additional, Sossa, Claudia, additional, Bernal Del Castillo, Teresa, additional, Sanz, Miguel A., additional, and Montesinos, Pau, additional

Published
2019
Full Text
View/download PDF

9. Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial

Author

Ribera, Josep-Maria, primary, Morgades, Mireia, primary, Ciudad, Juana, primary, Montesinos, Pau, primary, Barba, Pere, primary, García-Cadenas, Irene, primary, Moreno, María José, primary, Vives, Susana, primary, Esteve, Jordi, primary, Gil, Cristina, primary, Monsalvo, Silvia, primary, Artola, María Teresa, primary, Ribera, Jordi, primary, Genescà, Eulàlia, primary, Tormo, Mar, primary, Cervera, Marta, primary, Martínez-Carballeira, Daniel, primary, Novo, Andrés, primary, González-Campos, José, primary, Soria, Beatriz, primary, Bermúdez, Arancha, primary, Martínez, Aurelio López, primary, Mercadal, Santiago, primary, Fernández-Martín, Rosa, primary, Coll, Rosa, primary, Serrano, Josefina, primary, Amigo, Maria Luz, primary, Martínez-Sánchez, Pilar, primary, Bergua, Juan-Miguel, primary, Serrano-Maestro, Alfons, primary, Giménez Conca, Alberto, primary, Barrena, Susana, primary, Granada, Isabel, primary, Feliu, Evarist, primary, and Orfao, Alberto, primary

Published
2019
Full Text
View/download PDF

10. Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Author

Paiva, Bruno, primary, Martínez-Cuadron, David, additional, Bergua Burgues, Juan Miguel Miguel, additional, Vives, Susana, additional, Algarra, Jesús Lorenzo, additional, Tormo, Mar, additional, Martínez-Sánchez, Pilar, additional, Serrano, Josefina, additional, Herrera, Pilar, additional, Ramos, Fernando, additional, Salamero, Olga, additional, Lavilla, Esperanza, additional, Gil, Cristina, additional, Lopez Lorenzo, Jose Luiz, additional, Vidriales, Maria-Belen, additional, Labrador, Jorge, additional, Falantes, José F., additional, Sayas, Maria Jose, additional, Merino, Juana, additional, Alfonso, Ana, additional, Prosper, Felipe, additional, San-Miguel, Jesus F, additional, Sanz, Miguel A., additional, and Montesinos, Pau, additional

Published
2018
Full Text
View/download PDF

11. Incidence and Prognostic Impact of Secondary Neoplasia after High Dose Therapy Supported By Autologous Stem Cell Transplantation in Follicular Lymphoma. a Long Term Follow-up Analysis from the Geltamo Registry

Author

Jimenez Ubieto, ANA, primary, Grande, Carlos, additional, Caballero, Dolores, additional, Yañez, Lucrecia, additional, Novelli, Silvana, additional, Hernández, Miguel-Teodoro, additional, Manzanares, Marina, additional, Arranz, Reyes, additional, Ferreiro, José Javier, additional, Bobillo, Sabella, additional, Mercadal, Santiago, additional, Galeo, Andrea, additional, Lopez-Jimenez, Javier, additional, Moraleda, Jose Maria, additional, Vallejo, Carlos, additional, Albo, Carmen, additional, Pérez, Elena, additional, Marrero, Carmen, additional, Magnano, Laura, additional, Palomera, Luis, additional, Jarque, Isidro, additional, Martínez-Sánchez, Pilar, additional, Martín, Alejandro, additional, Coria, Erika, additional, López-Guillermo, Armando, additional, Salar, Antonio, additional, and Lahuerta, Juan José, additional

Published
2016
Full Text
View/download PDF

12. Comparison of Efficacy and Safety of Two Types of E.coli Asparaginase (Native or Pegylated) for Treatment of Adult Patients with High-Risk (HR), Philadelphia (Ph) Chromosome-Negative ALL Included in the Prospective MRD-Oriented Protocol ALL-HR-11 from the Spanish Pethema Group

Author

Ribera, Josep-Maria, primary, Morgades, Mireia, additional, Montesinos, Pau, additional, García-Cadenas, Irene, additional, Barba, Pere, additional, Soria, Beatriz, additional, Bermúdez, Arancha, additional, Moreno, MªJosé, additional, González-Campos, José, additional, Vives, Susana, additional, Gil, Cristina, additional, Abella, Eugenia, additional, Guàrdia, Ramon, additional, Bernal, Teresa, additional, Martínez-Sánchez, Pilar, additional, Amigo, MªLuz, additional, Mercadal, Santiago, additional, Serrano, Alfons, additional, López-Martínez, Aurelio, additional, Vall-llovera, Ferran, additional, Sánchez-Sánchez, MªJosé, additional, Peñarrubia, MªJesús, additional, Calbacho, María, additional, Méndez, Jose-Angel, additional, Bergua, Juan, additional, Cladera, Antònia, additional, Tormo, Mar, additional, García-Belmonte, Daniel, additional, Ciudad, Juana, additional, Feliu, Evarist, additional, and Orfao, Alberto, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results